meeting, please contact Kent Taylor, designated federal official, CDC, 4770 Buford Highway NE, MS F–29, Atlanta, Georgia 30341–3724; telephone (770) 488–7020, fax (770) 488–7024; e-mail: *ktaylor@cdc.gov*. The deadline for notification of attendance is November 14, 2002.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: October 8, 2002.

Burma Burch,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention,

[FR Doc. 02–26380 Filed 10–16–02; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Circulatory System Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 22, 2002, from 10 a.m. to 5:30 p.m., and October 23, 2002, from 8:30 a.m. to 4:30 p.m.

Location: Holiday Inn, Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Geretta Wood, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8320, ext. 143, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12625. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 22, 2002, the committee will discuss, make recommendations, and vote on a premarket approval application for a

drug-coated coronary artery stent intended to treat coronary artery obstructions and to help prevent instent stenosis. On October 23, 2002, the committee will discuss and make recommendations on a premarket notification (510(k)) submission for an arterial cannula intended to prevent an adverse neurological or limb threatening event. Background information for each day's topic, including the agenda and questions for the committee, will be available to the public one business day before the meeting on the Internet at http://www.fda.gov/cdrh/ panelmtg.html. Material for the October 22, 2002, session will be posted on October 21, 2002; material for the October 23, 2002, session will be posted on October 22, 2002.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 18, 2002. On both days, oral presentations from the public will be scheduled for approximately 30 minutes at the beginning of each topic and for approximately 30 minutes near the end of the committee deliberations. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 18, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams, Conference Management Staff, at 301–594–1283, ext. 113, as soon as possible.

FDA regrets that it was unable to publish this notice 15 days prior to the October 22, 2002, Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Circulatory System Devices Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 10, 2002.

Linda Arey Skladany,

Senior Associate Commissioner for External Relations.

[FR Doc. 02–26471 Filed 10–11–02; 4:26 pm] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Science Board to the Food and Drug Administration.

General Function of the Committee: The Board shall provide advice primarily to the Commissioner and the Senior Associate Commissioner for Science and Health and other appropriate officials on specific complex and technical issues as well as emerging issues within the scientific community. Additionally, the Board will provide advice to the agency on keeping pace with technical and scientific evolutions in the fields of regulatory science, formulating an appropriate research agenda, and upgrading its scientific and research facilities to keep pace with these changes. It will also provide the means for critical review of agency sponsored intramural and extramural scientific research programs.

Date and Time: The meeting will be held on October 25, 2002, 8 a.m. to 4:30 p.m.

Location: 5630 Fishers Lane, rm. 1066, Rockville, MD 20857.

Contact Person: Susan Bond, Office of the Commissioner (HF–33), Food and Drug Administration, rm. 17–35, 5600 Fishers Lane, Rockville, MD 20852, 301–827–6687, or e-mail: *sbond@oc.fda.gov*, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area), code 12603. Please call the Information Line for upto-date information on this meeting.

Agenda: The Board will hear and discuss counter terrorism initiatives at FDA with emphasis on those initiatives from: The Center for Food Safety and Applied Nutrition, the new Office of Cellular and Gene Therapy in the Center for Biologics Evaluation and Research, current research and efforts in the pregnancy labeling initiative, an update of the pharmaceutical manufacturing initiative from The Center for Drug Evaluation and Research, and an update of the management oversight of products.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 18, 2002. Open committee discussion will be held from 8 a.m. to 1 p.m.; an open public hearing will be held from 1 p.m. to 2 p.m.; and an open committee discussion will be held from 2 p.m. to 4:30 p.m. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 18, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Susan Bond at least 7 days in advance of the meeting.

FDA regrets that it was unable to publish this notice 15 days prior to the October 25, 2002, Science Board to the Food and Drug Administration Advisory Committee Meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Science Board to the Food and Drug Administration Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 10, 2002.

Linda Arey Skladany,

Senior Associate Commissioner for External Relations.

[FR Doc. 02–26472 Filed 10–11–02; 4:26 pm] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Children's Hospitals Graduate Medical Education (CHGME) Program Conference

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of public hearing.

SUMMARY: This document announces a public hearing to receive information and views on the notice that proposes methodologies and processes for the Children's Hospitals Graduate Medical Education (CHGME) Payment Program, published in the Federal Register (67 FR 60241) on September 25, 2002. The notice proposes methodology for: (1) Determining payments during the **CHGME** Payment Program's reconciliation process; (2) calculating indirect medical education (IME) payment; (3) disseminating CHGME Payment Program data, and (4) audit. This hearing will brief the public on the above methodologies and processes as well as hear public comments on the above. The public may also participate in the hearing by telephone as described below.

DATES: The public hearing will be held on October 22, 2002, from 2 p.m. to 3:30 p.m. EST.

ADDRESSES: The public hearing will be held in the Division of Medicine and Dentistry Conference Room, Bureau of Health Professions, Health Resources and Services Administration, Parklawn Building, 5600 Fishers Lane, Room 9A– 27, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT: Ayah E. Johnson, Ph.D., telephone: (301) 443–1058; Division of Medicine and Dentistry, Bureau of Health Professions, Health Resources and Services Administration, Parklawn Building, 5600 Fishers Lane, Room 9A–27, Rockville, Maryland 20857; or by e-mail at: *ajohnson@hrsa.gov*.

SUPPLEMENTARY INFORMATION: The CHGME Payment Program, as authorized by section 340E of the Public

Health Service (PHS) Act (the Act) (42 U.S.C. 256e), provides funds to children's hospitals to address disparity in the level of Federal funding for children's hospitals that result from Medicare funding for graduate medical education (GME). Pub. L. 106–310 amended the CHGME statute to extend the program through fiscal year 2005.

The hearing will again provide information on the proposed methodologies and processes contained in the September 25, 2002, CHGME Payment Program notice. The agenda for the hearing will include the following: (1) Methodology for determining payments during the CHGME Payment Program's reconciliation process; (2) calculating IME payment; (3) disseminating CHGME Payment Program data, and (4) audit. This hearing will brief the public on the above methodologies and processes as well as hear comments from the public on the above. Time will also be available for a question and answer period. Information about the Program can be found on the CHGME Payment Program Web site. The Web site address is http://bhpr.hrsa.gov/ childrenshospitalgme.

For security reasons, individuals wishing to attend the public hearing at the Parklawn Building must contact the CHGME Payment Program no later than October 17, 2002 to receive security clearance. These individuals should plan to arrive no later than 1:15 PM to accommodate security procedures. Individuals who do not contact the CHGME Payment Program by October 17, 2002 to receive security clearance will not be admitted to the Parklawn Building. In order for individuals to participate by telephone, they must dial: (888) 625–1617 and enter the corresponding pass code 52453. The pass code (52453) and Dr. Ayah Johnson's name, as call leader, are required to join the call. Telephone participants should call no later than 1:45 p.m. for logistical reasons.

In order to facilitate the public hearing, participants are asked to submit their questions in writing to Ayah E. Johnson, Ph.D., Division of Medicine and Dentistry, Bureau of Health Professions, Health Resources and Services Administration, Parklawn Building, 5600 Fishers Lane, Room 9A– 27, Rockville, Maryland 20857; or by email at *ajohnson@hrsa.gov* no later than October 17, 2002.

During the public hearing, individuals are asked to (1) hold their questions until the allotted question-and-answer period; (2) identify themselves and their hospital/organization before each question; and (3) address questions to